Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

Clin Pharmacokinet. 2019 May;58(5):685. doi: 10.1007/s40262-018-0726-6.

Yulan Qi^{1

2}, Kathleen McKeever³, Julie Taylor³, Christine Haller³, Wenjie Song^{3

4}, Simon A Jones⁵, Jack Shi³

¹ Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA. yulan.qi@gmail.com.
² BioMarin Pharmaceutical Inc., 105 Digital Dr., Novato, CA, 94949, USA. yulan.qi@gmail.com.
³ Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.
⁴ Ascendis Pharmaceutical Inc., 500 Emerson St., Palo Alto, 94301, USA.
⁵ Willink Unit, Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester and Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

Abstract

Introduction section, para 3, lines 2-4 which previously read.